How Earnings Beat At Amgen Stock Has Changed Its Investment Story

Amgen recently reported a 10% rise in second quarter revenue, continued to beat earnings and sales estimates, and maintained a dividend yield of 2.5% with annual increases of 8% from 2020 to 2025. The combination of consistent estimate beats, modest upward earnings revisions and faster dividend growth than Merck signals a business leaning on disciplined capital returns as well as expanding newer therapies. We will look at how Amgen's investment narrative is influenced by sustained dividend...